Compare INSM & TTWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | TTWO |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 47.2B |
| IPO Year | 2000 | 1997 |
| Metric | INSM | TTWO |
|---|---|---|
| Price | $176.09 | $251.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 20 |
| Target Price | $185.84 | ★ $269.25 |
| AVG Volume (30 Days) | ★ 3.8M | 1.3M |
| Earning Date | 02-19-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $447,022,000.00 | ★ $6,219,900,000.00 |
| Revenue This Year | $43.95 | $17.42 |
| Revenue Next Year | $130.35 | $38.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.34 | 13.98 |
| 52 Week Low | $60.40 | $177.35 |
| 52 Week High | $212.75 | $264.79 |
| Indicator | INSM | TTWO |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 53.55 |
| Support Level | $173.24 | $240.28 |
| Resistance Level | $179.44 | $260.04 |
| Average True Range (ATR) | 5.92 | 4.29 |
| MACD | -1.75 | 0.89 |
| Stochastic Oscillator | 32.48 | 55.01 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.